Article - 21/08/2009 Patenting and clinical trials go hand in hand Back when he was doing his degree thesis at the German Cancer Research Centre in Heidelberg the immunologist Prof. Peter Öhlschläger who now works at the University of Constance laid down the basic principles for developing an artificial gene for the treatment of cervical cancer. Prof. Öhlschläger is currently in the process of filing a patent for DNA vaccines for HPV. In the following interview the scientist says that the greatest challenges are…https://www.gesundheitsindustrie-bw.de/en/article/news/patenting-and-clinical-trials-go-hand-in-hand
Press release - 10/08/2009 How do immune cells recognise infectious pathogens? Scientists of the University of Heidelberg and the German Cancer Research Centre have clarified the functional principles of an important receptor for bacterial infections: immune cells recognise bacterial and viral pathogens with a receptor known as toll-like receptor 9 (TLR9), which mediates biochemical reaction chains in order to fend off intruders. This discovery made by the Heidelberg researchers paves the way to develop new anti-infective…https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-do-immune-cells-recognise-infectious-pathogens
Article - 30/07/2009 Keeping as many valuable attachments as possible The goal of many projects focusing on the purification of recombinant proteins is to rapidly and effectively remove substances and side products that would compromise the quality and quantity of biopharmaceutical compounds. A consortium of industrial and scientific partners is currently focusing on a different step in the biopharmaceutical production process: the goal is to keep as many as possible of the drugs’ ‘attachments’. The project focuses…https://www.gesundheitsindustrie-bw.de/en/article/news/keeping-as-many-valuable-attachments-as-possible
Press release - 30/07/2009 Boehringer Ingelheim set to outpace the market again After a successful start of the 2009 business year, Boehringer Ingelheim is expecting their sales growth to outpace the world pharmaceutical market; for the tenth time in succession. As announced by this second-largest German pharmaceuticals producer, the company posted growth in local currency (+ 8.3 per cent) over the previous year in the first six months of 2009. Net sales amounted to 6,388 million euro.https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-set-to-outpace-the-market-again
Press release - 30/07/2009 Why do hepatitis virus infections become chronic? The German Research Foundation (DFG) has approved funding for a new research project at the Universities of Freiburg and Heidelberg. The researchers are working on improving our understanding of the mechanisms that lead to chronic virus infections: how do hepatitis viruses manage to evade immunological defence reactions and survive in the organism without damaging the organism?https://www.gesundheitsindustrie-bw.de/en/article/press-release/why-do-hepatitis-virus-infections-become-chronic
Article - 14/07/2009 Tiny particles are a weapon against tumours Prostate carcinoma is one of the most common malignant diseases claiming more than 84000 lives per year in the EU and the United States. In cooperation with the University of Constance the Thurgau Biotechnology Institute BITg is working on ways to remove prostate carcinomas and other tumours that are difficult to treat by using tiny particles made of biologically degradable polyester. Prof. Dr. Marcus Groettrup and his team of researchers have…https://www.gesundheitsindustrie-bw.de/en/article/news/tiny-particles-are-a-weapon-against-tumours
Article - 02/07/2009 A virus that hides while it waits for an opportunity to replicate Thomas Mertens, Medical Director of the Institute of Virology in Ulm, has a strong scientific and clinical interest in the human cytomegalovirus (HCMV), a big virus with a big impact which, despite its size, is overshadowed by known viruses such as the HI virus that is the object of research for Mertens’ colleagues. HCMV research is a challenging area where quick successes are rare.https://www.gesundheitsindustrie-bw.de/en/article/news/a-virus-that-hides-while-it-waits-for-an-opportunity-to-replicate
Article - 10/06/2009 Dirk Linke - a vaccine is ready - just in case There is a well-known saying: travel broadens the mind. This is not the only consequence of travel – the biochemist Dr. Dirk Linke from Tübingen travelled to India on holiday and brought back an idea for a new scientific project. Since his return, his idea, the possibility of developing a vaccine with a wide-ranging effect against some of the most frequent diarrhoea pathogens, has even generated financial backing from prominent supporters.https://www.gesundheitsindustrie-bw.de/en/article/news/dirk-linke-a-vaccine-is-ready-just-in-case
Press release - 28/05/2009 CureVac Begins Clinical Study with mRNA Vaccine CureVac GmbH announced that the Paul-Ehrlich-Institute, the German regulatory authority for medicinal products, has approved the Clinical Trial Application (CTA) to begin a Phase I clinical study with RNActive® derived mRNA vaccine CV9201. The vaccine will be tested in patients with advanced non-small cell lung cancer who have been pre-treated with different therapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-begins-clinical-study-with-mrna-vaccine
Article - 16/05/2009 Mykotown Greentech AG uses mycorrhiza to keep plants going Mykotown Greentech AG offer mycorrhizal preparations that protect the plants against dehydration and bacteria. The fungi also enhance plant growth. The plants provide the natural soil fungi with carbon while the fungi help the plant to capture nutrients and liquids from the soil.https://www.gesundheitsindustrie-bw.de/en/article/news/mykotown-greentech-ag-uses-mycorrhiza-to-keep-plants-going
Press release - 30/04/2009 In the tubular system of human cells Scientists from the Hygiene Institute at the Heidelberg University Hospital have succeeded for the first time ever in showing the three-dimensional architecture of the dengue virus replication and assembly sites in human cells. Their paper was recently published in the renowned journal “Cell Host & Microbes”. https://www.gesundheitsindustrie-bw.de/en/article/press-release/in-the-tubular-system-of-human-cells
Article - 02/02/2009 CureVac enters premier biotech league with new cancer vaccine At present active immunotherapy seems to produce the best results in the treatment of cancer. The Tübingen-based biotech company CureVac is now hoping to achieve a breakthrough in cancer therapy with a worldwide unique vaccine. The first clinical trials have recently commenced.https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-enters-premier-biotech-league-with-new-cancer-vaccine
Press release - 14/01/2009 IND Approval for CureVac CureVac Receives IND Approval from the FDA to start its Phase I/IIa mRNA Vaccine Clinical Trial in Prostate Cancer. https://www.gesundheitsindustrie-bw.de/en/article/press-release/ind-approval-for-curevac
Press release - 10/12/2008 CureVac to Start First mRNA Vaccine Clinical Trial in Prostate Cancer The German regulatory authority has approved the Clinical Trial Application CTA to begin a Phase I clinical study with RNActive - derived mRNA vaccine CV9103. It will be tested in patients with hormone-refractory metastatic prostate cancer. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-to-start-first-mrna-vaccine-clinical-trial-in-prostate-cancer
Article - 05/12/2008 Secret biological recipes for a long life Staying healthy as you get older that is probably what many people would wish for. As part of the European research network LifeSpan 130 scientists are now looking into how to make this wish come true. Prof. Dr. Graham Pawelec from the University Hospital of Tübingen UKT is one of the 130 scientists and his principal focus is immunological ageing processes. https://www.gesundheitsindustrie-bw.de/en/article/news/secret-biological-recipes-for-a-long-life
Press release - 06/10/2008 Harald zur Hausen wins Nobel Prize in Medicine Harald zur Hausen the long-time chairman and scientific director of the German Cancer Research Centre DKFZ a member of the Helmholtz Society discovered that human papillomaviruses HPV lead to cervical cancer. His discovery led to the development of a vaccine for cervical cancer which is the third most frequent type of cancer in women.https://www.gesundheitsindustrie-bw.de/en/article/press-release/harald-zur-hausen-wins-nobel-prize-in-medicine
Article - 26/09/2008 University Hospital of Ulm combines forces The Comprehensive Infectious Diseases Centre at the University of Ulm was recently presented to the public. The centre is responsible for coordinating the cooperation between specialists in the diagnosis and therapy of complex infectious diseases.https://www.gesundheitsindustrie-bw.de/en/article/news/university-hospital-of-ulm-combines-forces
Article - 25/08/2008 Rare kidney tumour leads the way to a new cancer therapy Renal cell carcinoma is a rare disease. In addition, the disease is difficult to treat, and the majority of pharmaceutical companies find the development of new drugs for its treatment too financially risky. Their argument: the market is too small to make up for the high development costs. The Tübingen biotech company immatics was courageous enough to do so and will now be rewarded. The immatics scientists have developed a therapy that not only…https://www.gesundheitsindustrie-bw.de/en/article/news/rare-kidney-tumour-leads-the-way-to-a-new-cancer-therapy
Article - 29/07/2008 Frank Kirchhoff advances AIDS research by posing the right questions Frank Kirchhoff an AIDS researcher from Ulm has learnt to pose important questions and find the right answers during his post-graduate studies. This recipe has brought him and his research group international recognition and makes him one of the best AIDS researchers worldwide. Important publications within a very short time and numerous awards are clear evidence of his outstanding achievements. In addition he has just started a clinical trial…https://www.gesundheitsindustrie-bw.de/en/article/news/frank-kirchhoff-advances-aids-research-by-posing-the-right-questions
Article - 12/07/2008 1.4 mn € grants for immatics immatics biotechnologies GmbH announced that the company has received grants from three public research funding programs to advance its cancer immunotherapy programs with a special focus on glioblastoma and cancer stem cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/1-4-mn-grants-for-immatics
Article - 05/06/2008 CureVac: partnership with University of Florida, CureVac GmbH has entered into a partnership with the Department of Urology University of Florida Gainesville U.S. to jointly advance its lead candidate CV9103 into the clinical development. The alliance covers preclinical studies and a US phase III trial.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-partnership-with-university-of-florida
Press release - 28/05/2008 Printed biochips In a collaborative project scientists in Stuttgart and Heidelberg succeeded in cutting the production costs for highly complex peptide arrays by a factor of 100 at the same time as being able to increase the number of functional peptides by a factor of 20.https://www.gesundheitsindustrie-bw.de/en/article/press-release/printed-biochips
Article - 19/05/2008 "Fast-track" route to a PhD degree The Chemical Biology graduate school at Constance University was officially opened on 7th May 2008. It was created as part of Germanys excellence initiative and has been training doctoral students since the beginning of April 2008.https://www.gesundheitsindustrie-bw.de/en/article/press-release/fast-track-route-to-a-phd-degree
Article - 13/05/2008 A new method unmasks noroviruses on food Noroviruses often might be the causative agents of Nausea vomiting diarrhoea fever. The Chemical and Veterinary Investigation Office in Stuttgart has now developed a method that enables the detection of these viruses on food. https://www.gesundheitsindustrie-bw.de/en/article/news/a-new-method-unmasks-noroviruses-on-food
Article - 11/05/2008 New strategy against cervical cancer The German Cancer Research Centre and the Spanish company Chimera Pharma SL have signed an exclusive licensing and cooperation agreement. The two partners will develop a therapeutic vaccine against cervical cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/new-strategy-against-cervical-cancer